Hurim Biocell has been established since 2005. During the 1st decade after foundation, we focused on developing an adipose-derived stem cell therapy to treat incurable diseases, such as Vitiligo and Liver injury. In the meantime, we expanded our portfolio by including a commercial system of cell bank service and medical device production. Afterward, Hurim has been qualified with GMP, ISO certification, and the acquisition of more than 33 patents from both domestic and overseas.

As the company overgrows in recent years, there are significant improvements in Stem Cell Therapy: mastery of optimized protocol for cell isolation and cell culture. The R&D center finished pre-clinical trials of Vitiligo and Liver disease therapy. Now we are preparing to get ready for clinical trial phase 1.

Cell Banking System: the sales revenue jumped continuously after confirming a strategic partnership with A Plus, an insurance company ranked in the top five enterprises from local niche.

Medical device: the cutting-edge POCT solution to isolate Stromal Vascular Fraction (SVF) cells from human fat tissue under a fully automatic process. The device (HuriCell) has been officially registered and launched in Korea, Thailand, and Vietnam.

Hurim’s mission is to provide a one-stop service for regenerative medicine. Start from cell isolation, banking, clinical trial, and therapy commercialization to benefit more patients.